

AGENDA

Mayflower Renaissance Hotel, 1127 Connecticut Avenue NW

Wednesday, February 24th

4:00-8:00 pm *Registration open.....Outside Grand Ballroom*

4:30-6:00 pm Melanoma Forum: "Patients: From Passengers to Co-Pilots" (by invitation only).....Senate Room (Ground)

6:00-8:00 pm Opening Reception.....State Room (Ground)

- Debra Black, MRA Co-founder and Chair
- Louise Perkins, MRA Chief Science Officer
- Vicki Goodman, Bristol-Myers Squibb
- Eric Rubin, Merck & Co., Inc

Thursday, February 25th

6:30 am-6:00 pm *Registration open.....Outside Grand Ballroom*

7:00-8:15 am General Breakfast.....State & East Rooms (Ground)

7:00-8:15 am Young Investigators Breakfast: "New Frontiers in Melanoma Research" (by invitation only).....Chinese Room (Ground)

8:30-8:45 am Opening Remarks.....Grand Ballroom

- Margaret Anderson, Acting MRA President and CEO and Executive Director, *FasterCures*
- Louise Perkins, MRA Chief Science Officer

8:45-9:15 am Lecture: Paul Chapman, Memorial Sloan Kettering Cancer Center: How will we measure the efficacy of new drugs in clinical trials in the era of checkpoint and RAF inhibitors?

9:15-11:25 am Session: New Therapeutic Targets

Chair: Ronit Satchi-Fainaro

9:15-9:40 Gal Markel, Sheba Medical Center: Discovery of novel immune checkpoints in melanoma

9:40-10:00 Brent A. Hanks, Duke Cancer Institute: The influence of the tumor microenvironment on checkpoint inhibitor efficacy: Lessons learned from targeting the TGF-beta signaling pathway

10:00-10:20 Richard White, Memorial Sloan Kettering Cancer Center: Adipocytes in the melanoma microenvironment

10:20-10:40 *Break*

Thursday, February 25th (continued)

10:40-11:00 Nicholas Mitsiades, Baylor College of Medicine: Novel targeted therapies for uveal melanoma

11:00-11:25 Ronit Satchi-Fainaro, Tel Aviv University: Nanomedicine co-targeting of neuroinflammation in melanoma brain metastasis

11:25-11:55 am Lecture: Nicholas Restifo, U.S. National Cancer Institute: Qualities of highly effective anti-melanoma T cells

11:55 am- Session: Skin Screening for Melanoma

12:45 pm Chair: Martin Weinstock

11:55-12:20 Martin Weinstock, Rhode Island Hospital: Melanoma screening consequences

12:20-12:45 Sancy Leachman, Oregon Health and Science University: Mole Mapper: An iPhone app to measure moles

12:50-2:15 pm Lunch.....State & East Rooms (Ground)

“Melanoma: What’s on the Horizon”: Discussion with Michael Milken, Chairman, Milken Institute and MRA Board Member

- Boris Bastian, University of California, San Francisco
- Levi Garraway, Dana-Farber Cancer Institute
- Lynn Schuchter, University of Pennsylvania
- Suzanne Topalian, Johns Hopkins University

2:25-3:35 pm Session: Genomic Characterization of Melanoma

Chair: Jeffrey Trent

2:25-2:45 Priscilla Brastianos, Massachusetts General Hospital: Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets

2:44-3:10 Maryam Asgari, Massachusetts General Hospital and Iwei Yeh, University of California San Francisco: Using genomic technologies to comprehensively characterize acral melanomas

3:10-3:35 Jeffrey Sosman, Vanderbilt University and Jeffrey Trent, TGen: Comprehensive genomic and transcriptomic analysis of acral melanoma

3:35-3:50 pm *Break*

3:50-4:55 pm Session: Biomarkers of Therapeutic Response

Chair: Janis Taube

3:50-4:10 Michael Berger, Memorial Sloan Kettering Cancer Center: Delineating the heterogeneity of response to BRAF inhibition in melanoma

4:10-4:30 Navin Varadarajan, University of Houston: Quantitative single-cell biomarkers of melanoma immunotherapy

4:30-4:55 Janis Taube, Johns Hopkins University: Measuring PD-L1 in melanoma: Update and next steps

Thursday, February 25th (continued)

5:00 pm **Closing Remarks Day 1:** Laura Brockway-Lunardi, MRA Scientific Program Director

6:30-9:00 pm **Reception and Dinner**.....**National Museum of Women in the Arts**
1250 New York Ave NW, (202) 783-5000
Dress: Casual
6:15-7:15 pm: Transportation provided to museum; Pick up at Desales Street entrance of hotel
6:30-7:30: Reception and Art Viewing; 7:30: Dinner

Friday, February 26th

6:30-10:00 am *Registration open*.....*Outside Grand Ballroom*

7:00-8:30 am General Breakfast.....State Room (Ground)

7:00-8:30 am Industry Roundtable Breakfast (by invitation only).....Palm Court Ballroom (Ground)
“Building on the Momentum of Melanoma Clinical Development for 2016 and Beyond”

8:45-8:50 am **Opening Remarks Day 2:** Louise Perkins.....**Grand Ballroom**

8:50-9:20 am **Lecture:** Padmanee Sharma, MD Anderson Cancer Center,
From the clinic to the lab: Investigating immune responses to immune checkpoint therapies

9:20-11:20 am **Session: Combination Therapies**

Chair: Martin McMahon

9:20-9:45 Howard Kaufman, Rutgers University: Oncolytic virus immunotherapy: Current combination regimens and future directions

9:45-10:10 Craig Slingluff, University of Virginia: Combined immunotherapy of melanoma with long peptides and TLR agonists

10:10-10:30 *Break*

10:30-10:55 Omid Hamid, The Angeles Clinic and Research Institute: Combination anti-PD-L1 and BRAF inhibition

10:55-11:20 Martin McMahon, Huntsman Cancer Institute: The role of PI3'-kinase signaling in melanoma progression and maintenance

11:20-11:50 **Lecture:** Suzanne Topalian, Johns Hopkins University: Genetic and immunological heterogeneity of melanoma

11:50-12:00 pm **Closing Remarks:** Leon Black, MRA Co-Founder

12:00-1:00 pm Lunch available and departures.....State Room (Ground)